.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Harvard Business School
Cipla
McKinsey
Johnson and Johnson
Fish and Richardson
Daiichi Sankyo
AstraZeneca
Citi
Covington

Generated: September 20, 2017

DrugPatentWatch Database Preview

Lenvatinib mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for lenvatinib mesylate and what is the scope of lenvatinib mesylate freedom to operate?

Lenvatinib mesylate
is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lenvatinib mesylate has one hundred and two patent family members in thirty countries.

One supplier is listed for this compound.

Summary for Generic Name: lenvatinib mesylate

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list5
Clinical Trials: see list567
Patent Applications: see list11
Drug Prices:see low prices
DailyMed Link:lenvatinib mesylate at DailyMed

Pharmacology for Ingredient: lenvatinib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-002Feb 13, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-002Feb 13, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-002Feb 13, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-001Feb 13, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-001Feb 13, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-001Feb 13, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-001Feb 13, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-001Feb 13, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-002Feb 13, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-001Feb 13, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: lenvatinib mesylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,612,092Nitrogen-containing aromatic derivatives► Subscribe
8,372,981Nitrogen-containing aromatic derivatives► Subscribe
7,973,160Nitrogen-containing aromatic derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lenvatinib mesylate

Country Document Number Estimated Expiration
European Patent Office2567955► Subscribe
Canada2652442► Subscribe
China101443009► Subscribe
South Korea100870681► Subscribe
China1478078► Subscribe
China101024627► Subscribe
China101337933► Subscribe
Australia9598601► Subscribe
Luxembourg92858► Subscribe
European Patent Office1698623► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LENVATINIB MESYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015039,C1698623Lithuania► SubscribePRODUCT NAME: LENVATINIBAS; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528
1 5023-2015Slovakia► SubscribePRODUCT NAME: LENVATINIB MESYLAT; REGISTRATION NO/DATE: EU/1/15/1002/001 - EU/1/15/1002/002 20150601
90053-3Sweden► SubscribePRODUCT NAME: LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REG. NO/DATE: EU/1/15/1002 20150601
2015039Lithuania► SubscribePRODUCT NAME: LENVATINIBUM; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528
858Luxembourg► SubscribePRODUCT NAME: LENVATINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES OU UN HYDRATE DE CELUI-CI
C0070France► SubscribePRODUCT NAME: LENVATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI OU UN HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1002 20150601
2015 00053Denmark► SubscribePRODUCT NAME: LENVATINIB, ELLER ET FARMAKOLOGISK ACCEPTABELT SALT DERAF ELLER ET HYDRAT DERAF, HERUNDER LENVATINIB MESILAT; REG. NO/DATE: EU/1/15/1002/001-002 20150601
0764Netherlands► SubscribePRODUCT NAME: LENVATINIB, EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1002/001 -002 20150528
2015 00053Denmark► SubscribePRODUCT NAME: LENVATINIB, ELLER ET FARMAKOLOGISK ACCEPTABELT SALT DERAF ELLER ET HYDRAT, HERUNDER LEVATINIB MESILAT; REG. NO/DATE: EU/1/15/1002/001-002 20150601
2015000083Germany► SubscribePRODUCT NAME: LENVATINIB ODER EINES SEINER PHARMAZEUTISCH AKZEPTABLEN SALZE ODER EINES SEINER HYDRATE; REGISTRATION NO/DATE: EU/1/15/1002/001-002 20150528
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Teva
Moodys
Cantor Fitzgerald
Citi
Dow
McKinsey
Queensland Health
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot